Matches in DBpedia 2015-10 for { ?s ?p "ITI-007 is an investigational atypical antipsychotic which is currently under development by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb, for the treatment of schizophrenia. It is also being developed by Intra-Cellular Therapies for the treatment of bipolar disorder, depression, and sleep and behavioral disturbance in dementia, autism, and other neuropsychiatric disorders. As of May 2015, ITI-007 is in phase III clinical trials for schizophrenia."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- ITI-007 abstract "ITI-007 is an investigational atypical antipsychotic which is currently under development by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb, for the treatment of schizophrenia. It is also being developed by Intra-Cellular Therapies for the treatment of bipolar disorder, depression, and sleep and behavioral disturbance in dementia, autism, and other neuropsychiatric disorders. As of May 2015, ITI-007 is in phase III clinical trials for schizophrenia.".
- ITI-007 comment "ITI-007 is an investigational atypical antipsychotic which is currently under development by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb, for the treatment of schizophrenia. It is also being developed by Intra-Cellular Therapies for the treatment of bipolar disorder, depression, and sleep and behavioral disturbance in dementia, autism, and other neuropsychiatric disorders. As of May 2015, ITI-007 is in phase III clinical trials for schizophrenia.".